Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia

Key Points

• To highlight a rare case of visceral leishmaniasis arising in a patient with multiple sclerosis treated with fingolimod, emphasizing the risks associated with lymphopenia.
• Case report of a patient with multiple sclerosis on fingolimod therapy.
• Evaluation of the patient's clinical history and lymphocyte levels.
• Analysis of infection and treatment outcomes.
• The patient developed visceral leishmaniasis after fingolimod treatment due to lymphopenia.
• Treatment adjustments were necessary to manage the infection effectively.
• This case prompts awareness of potential infections in patients on fingolimod.

Abstract